

# Kidney Cancer (Renal Cell Carcinoma) Pathways

Patient Name: \_\_\_\_\_

Date of Birth: \_\_\_\_\_

Member Number: \_\_\_\_\_

Treatment Start Date: \_\_\_\_\_

**Pathology:** \_\_\_\_\_

**Stage:** \_\_\_\_\_

**Line of Therapy:**  Neoadjuvant/Pre-Op  Adjuvant/Post-Op  
 1<sup>st</sup> Line  2<sup>nd</sup> Line  3<sup>rd</sup> Line  3<sup>rd</sup> Line+

**ECOG Performance Status:** \_\_\_\_\_ **ICD-10 Code:** \_\_\_\_\_

**Biomarkers/Characteristics:** (Select all that apply)

Microsatellite Instability:  dMMR/MSI-H  MSI-L  Not Reported

NTRK Fusion:  Negative  Positive  Not Reported

Renal Cancer Risk:  Poor  Intermediate  Good

Prior Therapy: \_\_\_\_\_

## Metastatic Disease | First Line of Therapy (1<sup>st</sup> Line) | Clear Cell Carcinoma

Nivolumab (Opdivo) and ipilimumab (Yervoy)

Pembrolizumab (Keytruda) and axitinib (Inlyta)

## Metastatic Disease | Second or Subsequent Lines of Therapy (2<sup>nd</sup> Line+) | Clear Cell Carcinoma

Nivolumab (Opdivo)

**Note:** Pathways are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered.

